Dr. Lin completed his Sc.B. in Biochemistry with honors at Brown University before going on to train in the NIH-supported Medical Scientist Training Program (MSTP) at the University of Alabama at Birmingham (UAB), receiving both an MD and a PhD in Cell Biology. His dissertation research in the lab of Fang-Tsyr (Fannie) Lin centered around thyroid hormone receptor interacting protein 6 (TRIP6), an adaptor protein that is upregulated in a number of malignancies, including ovarian cancer and glioblastoma. His work illustrated how TRIP6 specifically regulates p27KIP1, a CDK inhibitor that is an important prognostic determinant in cancer. He went on to complete his residency in Internal Medicine and fellowship in Hematology and Oncology as part of the ABIM Research Pathway at UAB. During this time, he did his postdoctoral fellowship in the lab of Lalita Shevde-Samant, where his research focused on the role of the Hedgehog pathway in regulating DNA repair, particularly the role of GLI1 in enabling the repair of double strand breaks in ribosomal DNA (rDNA). After completing his training, he joined the Department of Medicine at UAB as an Instructor in the Division of Hematology and Oncology with a clinical focus in lung cancer and sarcoma and a research focus in precision oncology. He is the Associate Director of the UAB Molecular Tumor Board and also serves on the UAB MSTP Advisory Committee.